The Forgotten Hepatitis: How Gilead's Hepcludex Just Ended Decades of Therapeutic Silence for HDV

There is a particular kind of medical neglect that accumulates quietly, over decades, in the space between what science understands and what medicine can actually offer. Hepatitis delta virus has occupied that space for a long time. On May 22, 2026, the FDA closed it, granting accelerated approval to Gilead Sciences' Hepcludex (bulevirtide-gmod) as the first and only approved treatment for chronic HDV infection in the United States. For the estimated 40,000 to 80,000 Americans living with this disease, and the roughly 12 million people affected worldwide, the approval represents the end of a therapeutic void that has persisted since the virus was first identified in the late 1970s.

The story of why it took this long is worth understanding, because it illuminates something important about how the pharmaceutical industry and regulatory system allocate attention, and what happens to patients when a disease falls outside the commercial mainstream.

What HDV Actually Is, and Why It Is So Dangerous

Hepatitis delta virus is biologically unusual. It cannot infect a person on its own. HDV is a defective satellite virus that requires the hepatitis B virus to replicate, using HBV's surface antigen as a kind of molecular scaffold to assemble new viral particles. This dependency means that HDV infection only occurs in individuals who already have chronic HBV, either as a simultaneous co-infection or as a superinfection in someone already living with hepatitis B.

That biological quirk has contributed to HDV's relative obscurity in public health discourse. But the clinical consequences of the co-infection are anything but obscure. Chronic HDV is considered the most severe form of viral hepatitis. Patients with HDV and HBV co-infection face a markedly higher risk of rapid liver fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure compared to those with HBV alone. Mortality rates in cirrhotic HDV patients can reach 50 percent within five years. The disease progresses faster, the complications arrive sooner, and the outcomes are worse. Until last week, there was nothing specifically approved in the United States to treat it.

The treatment landscape that existed before Hepcludex was not empty, but it was inadequate. Pegylated interferon alfa, a broad-spectrum antiviral with a difficult tolerability profile, has been used off-label for HDV for years. It suppresses viral replication in some patients but rarely achieves durable undetectable HDV RNA, and its side effects, including flu-like symptoms, depression, and cytopenias, limit its use in many patients. For a disease that requires long-term management, an off-label therapy with significant toxicity and modest efficacy is a poor foundation for clinical care.

What Bulevirtide Does and Why It Is Different

Hepcludex works through a mechanism that is genuinely novel in the hepatitis space. Bulevirtide is a first-in-class entry inhibitor that blocks the sodium taurocholate co-transporting polypeptide, known as NTCP, a bile acid transporter on the surface of liver cells that both HDV and HBV use to gain entry into hepatocytes. By occupying the NTCP receptor, bulevirtide prevents both viruses from infecting new liver cells, addressing a key step in the viral lifecycle rather than suppressing replication after infection has already occurred.

The Phase 3 MYR301 trial, which formed the primary basis for the FDA's accelerated approval, enrolled adults with chronic HDV and randomized them to immediate treatment with bulevirtide 8.5 mg once daily or to a delayed treatment control group. At Week 48, the primary endpoint of combined virologic and biochemical response, defined as undetectable HDV RNA or at least a two-log reduction from baseline, plus normalization of alanine aminotransferase, was achieved in 48 percent of patients in the bulevirtide group compared with 2 percent in the control group. That is not a marginal separation. It is a result that reflects a drug doing something the disease's natural history and prior treatment options could not.

The durability of the response is equally important. At Week 96, the rate of undetectable HDV RNA in the treatment group reached 36 percent, rising to 50 percent at Week 144. For a disease defined by its relentless progression, the trajectory of viral suppression over nearly three years of treatment is a clinically meaningful signal. The safety profile was generally manageable, with the most notable concern being a boxed warning about severe acute exacerbations of both HDV and HBV that can occur if the drug is discontinued, requiring careful monitoring for at least six months after stopping treatment.

The Structural Problem Behind the Delay

The more uncomfortable question raised by this approval is not scientific. It is systemic. Bulevirtide has been approved in the European Economic Area since 2020, where it has been available at a 2 mg dose for several years. The US approval, at a higher 8.5 mg dose supported by the MYR301 data, arrived more than five years later. That gap is not primarily a reflection of scientific uncertainty. It reflects the economics of rare disease drug development and the way those economics shape which patient populations receive sustained pharmaceutical attention.

HDV affects a relatively small number of people in the United States, concentrated in populations that include people who inject drugs, immigrants from regions where HBV is endemic, and individuals with occupational exposure to blood. These are not populations that generate the kind of commercial projections that drive large-scale drug development investment. The FDA's decision to grant Hepcludex Breakthrough Therapy Designation, Orphan Drug Designation, and Priority Review reflects the agency's recognition that the disease meets the threshold for expedited attention. But those designations are reactive instruments. They accelerate review once a sponsor has committed to development. They do not create the initial incentive to develop a drug for a disease that the market has largely ignored.

Gilead's commitment to completing the MYR301 trial and pursuing US approval deserves acknowledgment, particularly given the company's deep history in viral hepatitis. The same scientific infrastructure that produced curative treatments for hepatitis C has now delivered the first approved therapy for the most severe form of viral hepatitis. That continuity of institutional focus matters in a field where rare diseases can languish for decades without a sponsor willing to do the work.

What Comes Next for Patients and the Field

The accelerated approval pathway means that Gilead has committed to a confirmatory long-term outcomes trial to verify clinical benefit beyond the virologic and biochemical endpoints that supported the current approval. That trial is already underway. The distinction matters because accelerated approval is based on a surrogate endpoint, in this case HDV RNA suppression and ALT normalization, that is reasonably likely to predict clinical benefit but has not yet been directly demonstrated in terms of reduced rates of cirrhosis, liver cancer, or liver-related death. The confirmatory data will be essential for establishing the drug's full clinical value and for informing long-term prescribing decisions.

The approval also raises a question about diagnosis. HDV testing is not routinely performed in all patients with chronic HBV in the United States, despite guidelines recommending it. An estimated 90 percent of HDV-infected individuals globally remain undiagnosed, a figure that reflects both the disease's geographic concentration and the inconsistency with which clinicians test for it. A drug that works cannot help a patient who has never been told they have the disease it treats. The commercial launch of Hepcludex will need to be accompanied by sustained efforts to improve HDV testing rates among the HBV-infected population, or the approval's clinical impact will be substantially smaller than the trial data suggest it could be.

For the broader infectious disease field, the Hepcludex approval is a reminder that the pipeline of approved treatments for serious viral diseases remains incomplete in ways that are not always visible from the vantage point of the commercial mainstream. Hepatitis delta virus has been known to science for nearly fifty years. The first approved treatment for it in the United States arrived last week. The patients who have been living with this disease in the intervening decades did not have the luxury of waiting for the market to catch up. The ones who are alive today finally have something to offer them.